Analyst consensus rating
Marker Therapeutics Analyst Rating: Strong Buy
MRKR is rated Strong Buy by 3 analysts with a $7.87 target. As of 2026-08-26.
Direct answer
Marker Therapeutics's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.87.
Forecast evidence checked August 26, 2026.
Get free Marker Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.45
- Average price target
- $7.87
- High price target
- $10.00
- Low price target
- $5.60
- Low target gap
- +286.2%
- Target upside
- +442.5%
- High target gap
- +589.7%
- Target range width
- 303.4%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Marker Therapeutics?
Marker Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $7.87.
How far are Marker Therapeutics's low and high targets from the recorded price?
The low target implies +286.2%, while the high target implies +589.7%.
How many analysts are included in Marker Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Marker Therapeutics's target upside or downside calculated?
The average target of $7.87 is divided by the recorded price of $1.45, then one is subtracted to produce +442.5%. This does not guarantee a future return.
When was Marker Therapeutics's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.